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Abstract: This article reviews the role of an extended-release formulation of pramipexole in 
the treatment of Parkinson’s disease at an early stage. Pramipexole is a nonergot D2/D3   synthetic 
aminobenzothiazole derivative that is effective as monotherapy in early disease and as an adjunct 
to levodopa in patients with motor fluctuations. Although levodopa is the current “gold standard” 
for treatment of Parkinson’s disease, its effectiveness fades rapidly and its use results in serious 
motor fluctuations (on-off, wearing-off, freezing, involuntary movements) for most patients 
with the disease. Pramipexole has selective actions at dopamine receptors belonging to the D2 
subfamily, where it possesses full activity similar to dopamine itself. Its preferential affinity 
for the D3 receptor subtype could contribute to its efficacy in the treatment of both the motor 
and psychiatric symptoms of Parkinson’s disease. The best approach to medical   management 
of early Parkinson’s disease remains controversial. While enormous progress has been made in 
the treatment of the disease, challenges still remain. A variety of treatment-related and patient-
related factors must be taken into account when making these decisions. The current approach 
to treatment of early Parkinson’s disease depends in part on individual patient factors,   including 
age, severity and nature of symptoms and their impact, presence of cognitive dysfunction, 
possible underlying behavioral factors predisposing to impulse control disorders, and other 
comorbidities. Today, the once-daily extended-release formulation of pramipexole offers the 
advantages of easy continuous delivery of drug and convenience to patients, particularly early 
in the disease when monotherapy is the rule. Thus, a new “levodopa-sparing” paradigm for 
treating Parkinson’s disease may now be possible, whereby patients are initially treated with 
pramipexole and levodopa is added only as necessary.
Keywords: Parkinson’s disease, treatment, pramipexole, dopamine agonist, motor co  mplications, 
continuous dopaminergic stimulation
Introduction
Parkinson’s disease, named for James Parkinson who wrote a monograph entitled “An 
essay on the shaking palsy” in 1817,1 is a progressively disabling   neurodegenerative 
condition that causes dopamine deficiency in the nigrostriatal system and is treated 
most commonly by dopamine replacement with the   precursor levodopa, but agonists 
at dopamine receptor sites are used as initial therapy in the early stages of the disease.2 
Pathologically, there is a loss of neurons within the substantia nigra pars compacta and 
other subcortical nuclei, associated with widespread Lewy bodies,3 which are   abnormal 
aggregates of proteins that develop inside neurons. Parkinson’s disease manifests 
clinically after loss of approximately 50% of dopaminergic neurons.4
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Parkinson’s disease is the second most common neurode-
generative disorder, affecting 1.4% of the population over the 
age of 55 years.5 An estimated 5 million people throughout 
the world have Parkinson’s disease, with one million indi-
viduals each in the US and in Europe having the disorder. 
With the aging of the population and the substantial increase 
in the number of at-risk individuals older than 60 years, it 
is anticipated that the prevalence of Parkinson’s disease will 
increase dramatically in the coming decades.6 Interestingly, 
a large prospective study found that incidence rates rise 
steeply through to age 89 years; then lifetime risk plateaus 
after age 90 years.7 The incidence of Parkinson’s disease has 
been reported to be higher in men than in women, but only 
among patients older than 60 years.8 Several studies suggest 
a higher incidence of Parkinson’s disease in whites than in 
African-Americans or Latin Americans. This may be due to 
true biological differences in the risk of Parkinson’s disease 
or to underdiagnosis because of barriers to health care, such 
as education or cultural beliefs about health and aging.9
Many of the motor manifestations of the disease can 
be attributed to the disappearance of dopamine-producing 
neurons in the substantia nigra pars compacta and the con-
sequent severe depletion of dopamine in the striatum into 
which the nigral nerve terminals project. The degree of 
degeneration of these dopaminergic terminals correlates best 
with the bradykinesia aspect of Parkinson’s disease, which is 
an essential diagnostic criterion for the disease, rather than 
tremor or rigidity.10 The cardinal clinical manifestations 
of Parkinson’s disease are tremor, rigidity, bradykinesia, 
and gait dysfunction (postural instability). Usually there is 
asymmetry, with one side being affected first and remain-
ing worse throughout the disease. It is now appreciated that 
Parkinson’s disease is also associated with many nonmotor 
features, including autonomic dysfunction, pain and sen-
sory disturbances, mood disorders, sleep impairment, and 
dementia. Nonmotor symptoms may present before motor 
symptoms are manifest.11
Parkinson’s disease is characterized pathologically by 
degeneration of dopaminergic neurons in the substantia nigra 
pars compacta coupled with intracytoplasmic proteinaceous 
inclusions known as Lewy bodies. Parkinson’s disease is 
also associated with extensive nondopaminergic pathology, 
which involves cholinergic neurons of the nucleus basalis 
of Meynert, norepinephrine neurons of the locus coeruleus, 
serotonin neurons in the midline raphe, as well as neurons 
in the cerebral cortex, brainstem, spinal cord, and per  ipheral 
autonomic nervous system.12 Indeed, studies suggest that 
nondopaminergic pathology, particularly in the dorsal 
motor nucleus and olfactory regions, precedes the onset of 
d  opaminergic pathology in the substantia nigra.13
Effective treatment of the motor symptoms of Parkinson’s 
disease involves compensating the striatum and output nuclei 
of the basal ganglia for loss of degenerating nigrostriatal dop-
aminergic input. There is now accumulating evidence that the 
combination of progressive pathology in Parkinson’s disease, 
changes in drug pharmacodynamics, and the pulsatile manner 
in which short-acting dopaminergic agents stimulate striatal 
dopamine receptors are key contributing factors in priming 
of the basal ganglia for induction of motor complications.14
Logically, once the diagnosis of Parkinson’s disease is 
made, treatment should be started immediately with an effec-
tive neuroprotective agent. However, to date, no treatment 
has been proven to slow progression of Parkinson’s disease, 
although this is an area of ongoing research.15 The 20th century 
witnessed unheralded advancements in medical and surgical 
management for Parkinson’s disease, the foremost of which 
was the discovery that the dopamine precursor, levodopa, 
substantially improves motor symptoms.16 A majority of 
patients experience motor fluctuations, dyskinesia, or other 
complications after 5 years of treatment and the frequency 
increases as the disease duration is prolonged. Off periods 
of wearing-off and on-off and severe dyskinesia markedly 
interfere with daily activities and compromise the quality of 
life of patients with Parkinson’s disease. Much research into 
developing additional symptomatic medications has been 
focused on avoiding these complications.17 Neurologists have 
several choices of drugs that have been shown to be effective 
for the treatment of the symptoms of Parkinson’s disease.17 
Dopamine agonists are being used increasingly as first-line 
treatment for the disease, but there remains uncertainty about 
their clinical and cost-effectiveness relative to levodopa.17 
Long-acting dopamine agonists provide more physiological 
dopaminergic stimulation. The recommendation supported 
by evidence from randomized controlled trials is to start 
treatment with a dopamine agonist and add levodopa when 
it becomes necessary.18–20 In this review, the benefits of using 
dopamine agonists in the management of early Parkinson’s 
disease would be discussed, along with recent evidence of 
the convenience of once-daily use of an extended-release 
formulation of pramipexole.
Dopamine agonists
The use of oral dopamine agonists for the treatment 
of   Parkinson’s disease dates back to the 1970s when 
  bromocriptine was first introduced.17 The symptomatic 
efficacy of dopamine agonists to treat Parkinson’s disease is 
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firmly established, and several studies have also shown that 
early use of these drugs as initial monotherapy is associated 
with a reduced long-term incidence of motor complica-
tions (ie, motor fluctuations and dyskinesia) compared with 
levodopa.19,21–24 Although this evidence has led to dopamine 
agonists being classified as first-line options for initial mono-
therapy in early Parkinson’s disease in many national and 
international guidelines,25,26 there have also been concerns 
about the safety profile of these drugs in the long term. These 
concerns relate to the risk of developing daytime somnolence, 
hallucinations, peripheral edema, hypersexuality, impulse 
control disorders, and heart valve fibrosis.17 In the past 
decade, nonergot dopamine agonists have largely supplanted 
the ergot agonists as the dopamine agonists of choice for the 
treatment of Parkinson’s disease. Pramipexole and ropinirole 
are the two most widely used drugs. Ropinirole has been 
approved for the treatment of early Parkinson’s disease in a 
transdermal (patch) delivery formulation, but had been vol-
untarily withdrawn from the market in the US because of a 
tendency for the drug to crystallize in the patch.27 Although 
the use of dopamine agonists to improve motor symptoms 
remains the basis of treatment,28 the design of pharmaco-
therapy is evolving toward more continuous drug delivery 
to provide more continuous stimulation of striatal dopamine 
receptors29 and more convenience for patients.
Pramipexole
The dopamine agonist pramipexole30 (Sifrol®, Mirapex®, 
Mirapexin®, and Pexola®; Boehringer Ingelheim GmbH, 
Ingelheim, Germany) is a nonergot D2/D3 synthetic amin-
obenzothiazole derivative that is effective as monotherapy 
in early Parkinson’s disease and as an adjunct to levodopa 
in patients with motor fluctuations and advanced idiopathic 
Pa  rkinson’s disease.31–33 An extended-release formulation 
(Sifrol Retard ER®, Mirapex ER®, Mirapexin ER®, and Pexola 
ER®; B  oehringer Ingelheim GmbH) that could be taken 
once daily might provide an effective and simple alternative 
treatment. Once-daily therapies have been shown to promote 
better adherence (compliance),34–36 which in Parkinson’s 
disease might lead to off-time37 and theoretically a reduced 
risk for motor complications.38 Initial monotherapy with 
pramipexole is among the first-line treatment approaches 
to early Par  kinson’s disease recommended in major inter-
national guidelines as a means to delay the occurrence of 
motor complications induced by levodopa.25,39 Pramipexole 
is also efficacious and safe as adjunctive therapy to reduce 
motor response oscillations in levodopa-treated patients with 
Pa  rkinson’s disease.39–42 However, recent studies have clearly 
established that   once-daily drugs are associated with the high-
est value for total or daily drug adherence and, in particular, 
timing adherence.36 The currently available immediate-release 
formulation of pramipexole is taken three times daily. Dosing 
frequency has been identified as a major factor for subopti-
mal drug adherence in Parkinson’s disease.43 A once-daily 
extended-release formulation of pramipexole and three times 
daily pramipexole immediate-release have similar exposure 
over 24 hours, and might therefore offer benefits in terms of 
convenience, compliance, and mode of dopamine delivery.43 
The new extended-release formulation of pramipexole which 
has been launched in Europe and the US improves ease of use 
and compliance and provides a more continuous therapeutic 
effect over 24 hours.44 The extended-release formulation is 
associated with fewer fluctuations in plasma pramipexole 
concentrations over this period. The United States Food and 
Drug Administration (FDA) has approved pramipexole dihy-
drochloride extended-release tablets for the signs and sy  mptoms 
of early idiopathic Parkinson’s disease.44 Pramipexole 
extended-release for early Parkinson’s d  isease is a posi-
tive development in the treatment of this disease. This new 
once-daily treatment has a more convenient dosing schedule, 
offering greater flexibility as someone with early Parkinson’s 
disease plans his or her day. Extended-release pramipexole 
dihydrochloride tablets for oral administration are available 
in strengths of 0.375, 0.75, 1.5, 3, and 4.5 mg.31 In general, 
patients tend to prefer once-daily dosing to a more frequent 
regimen because of convenience. Before initiating any treat-
ment, the benefit–risk ratio to the individual patient must be 
considered. For pramipexole to be used in the treatment of 
Parkinson’s disease, it is necessary to take into account the 
available evidence regarding its symptomatic efficacy, effect 
on delaying long-term levodopa-related motor complications, 
beneficial effect on nonmotor symptoms such as depression, 
and its safety and tolerability profile. Findings from clinical 
studies show that pramipexole extended-release is superior 
to placebo and has benefits comparable with the currently 
available pramipexole immediate-release in early Par  kinson’s 
disease. Pramipexole extended-release improved the symp-
toms of Parkinson’s disease in three well designed trials in 
adults with early or advanced disease, as measured by changes 
from baseline in the sum of the Unified Parkinson’s Disease 
Rating Scale parts II and II subtotal scores. In one of the stud-
ies, in early Parkinson’s disease, the feasibility of an overnight 
switch from pramipexole immediate-release to the once-daily 
extended-release formulation was s  tudied.45 In a 9-week 
study, the majority of patients with early P  arkinson’s disease 
who were receiving stable pramipexole   immediate-release 
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tr  eatment were successfully switched to pramipexole extended-
release. Both formulations were safe and well tolerated, with 
the rate of adverse events being generally similar to that with 
pramipexole immediate-release. In patients with early 
Parkinson’s disease, several prospective, double-blind, con-
trolled trials have shown initiation of therapy with a long-
acting dopamine agonist to be associated with a lower risk of 
motor complications compared with initiation on levodopa.46,47 
Once the decision is made that dopaminergic therapy should 
be initiated (for whatever reason), several factors impact on 
the choice of treatment, particularly whether to use levodopa 
or a dopamine agonist. The long-standing belief that levodopa 
has potential neurotoxic effects, primarily through its ability 
to enhance oxidative stress on remaining dopaminergic neu-
rons has been largely abandoned.48 Thus, the advantage of the 
“levodopa-sparing” effects of dopamine agonists in reducing 
oxidative stress has little current support. The strongest jus-
tification for initiation of treatment with a dopamine agonist 
is the repeated demonstration that this treatment approach is 
associated with a significant reduction in the risk of develop-
ing motor complications, particularly dyskinesias, compared 
with levodopa.19,20,22,23 Dopamine agonists have been regularly 
shown to provide less improvement on rating scale evaluations 
than levodopa, although it has been argued that the differences 
demonstrated in the early treatment trials were not clinically 
meaningful.19,49 The cognitive state of the patient and their 
financial resources should be taken into account when decid-
ing on initial therapy for Parkinson’s disease.
Young-onset Parkinson’s disease (YOPD) is arbitrarily 
defined as symptom onset between the ages of 21 and 39 years 
inclusive. However, different studies have used an upper 
age cut-off of anywhere from 40 to 50 years. Juvenile-onset 
Parkinson’s disease is defined as Parkinson’s disease onset 
before the age of 21 years.50 YOPD is uncommon, but in 
Japan the prevalence is higher. Diagnostic considerations in 
YOPD include Wilson’s disease, toxins, genetic Pa  rkinson’s 
disease, and other neurodegenerative disorders. YOPD 
patients differ from the typical onset Parkinson’s disease 
patients, with dystonia being more common. In addition, 
they have a long course of disease and are more prone to 
levodopa-induced dyskinesia. Some studies have shown 
that up to 95% of patients develop dyskinesia after 5 years 
of levodopa therapy.22 Therefore, YOPD patients are good 
candidates for therapies other than levodopa. These include 
anticholinergics, amantadine, monoamine oxidase B inhibi-
tors, and dopamine agonists. The widely practiced initiation 
of dopaminergic treatment with dopamine agonists to delay 
dyskinesias is still probably justified in young-onset patients 
who develop dyskinesias almost universally within the early 
treatment years.50 YOPD patients are frequently good candi-
dates for surgical treatment of Parkinson’s disease. Currently, 
deep brain stimulation of the subthalamic nucleus is offered 
to this group of patients with remarkable success as far as 
motor symptoms are concerned. It is essential to listen to the 
experiences of patients.
An interesting study compared quality of life between 
a group of patients who started with dopaminergic drugs 
versus a group left untreated for 18 months after diagnosis. 
The quality of life was higher in the group treated early.51 
When considering the issue of when to start symptomatic 
treatment, both patients and clinicians should be guided 
primarily by the current functional disabilities experienced 
by the patients during their everyday activities (eg, employ-
ment, hobbies, and self-care). The optimal time frame for 
onset of therapy has not been clearly defined. Once parkin-
sonian signs start to have an impact on the patient’s life, 
initiation of treatment is recommended. For each patient, 
the choice between the numerous effective drugs available 
is based on a subtle combination of subjective and objective 
factors.27 These factors include considerations related to the 
drug (eg, efficacy for symptomatic control of parkinsonism/
prevention of motor complications, safety, practicality, 
costs), to the patient (eg, symptoms, age, needs, expec-
tations, experience, comorbidity, socioeconomic level), 
and to his/her environment (including drug availability 
according to national markets in the European Union, and 
variability in economic and health insurance systems). 
However, based on the available level of evidence alone, 
two main issues are usually considered when initiating 
a symptomatic therapy for early Parkinson’s disease, ie, 
symptomatic control of parkinsonism and prevention of 
motor complications.
Conclusion
Many physicians routinely use dopamine agonists in early 
Parkinson’s disease because they provide symptomatic 
benefits with a low risk of motor complications. It is impor-
tant to recognize that the treatment of Parkinson’s disease 
is highly individual and that the physician must use his or 
her best judgment and consider the wishes of the patient 
in making therapeutic decisions. Pramipexole is generally 
well tolerated and efficacious for treating motor symptoms 
in both early and advanced Parkinson’s disease. Its efficacy 
and tolerability are similar in African-Americans, Asians, 
Caucasians, and Hispanics.52 As initial treatment, pramipex-
ole may delay the onset of dyskinesias by delaying the start 
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of levodopa therapy. It appears to have beneficial effects 
on nonmotor symptoms, such as depression, and it may 
improve treatment-resistant tremor, anhedonia, and weight 
loss.52,Pramipexole seems to have neuroprotective effects in 
vitro and in animal models, but these findings have not been 
replicated in humans. Compared with levodopa, pramipex-
ole therapy is associated with a higher risk for developing 
hallucinations, somnolence (and indirectly, attacks of 
sudden onset of sleep), impulse control disturbances, and 
peripheral edema, but not cardiac valvular disease. The risk 
for adverse events increases with patient age, pramipexole 
dose, severity of Parkinson’s disease, concomitant combi-
nation therapy, and comorbidity, especially cardiovascular. 
Continued pharmacovigilance in respect to adverse events, 
especially increased somnolence, cardiac valvulopathy, 
and psychiatric effects is necessary. Although pramipexole 
therapy is more costly than levodopa, the cost-effectiveness 
increases over time due to a higher gain in quality of life. 
More research is needed regarding the neuroprotective 
potential of pramipexole and its impact on cognition, apathy, 
fatigue, quality of life, and treatment costs in Parkinson’s 
disease. Pramipexole seems especially well suited for 
younger patients with Parkinson’s disease (,65 years), 
without cognitive disturbances, with low comorbidity, at 
high risk for developing dyskinesias, and with particular 
features of Parkinson’s disease shown to be responsive to 
pramipexole. Pramipexole new extended-release offers 
an important opportunity to simplify drug regimens for 
patients with Parkinson’s disease while maintaining symp-
tom control. Finally, it should be reiterated that pramipexole 
and other drugs that are used to alleviate symptoms in early 
Parkinson’s disease are unlikely to modify disease progres-
sion, and future therapies must combine symptomatic and 
disease-modifying agents.
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